740 Heinz Avenue Berkeley, CA 94710 Phone: 510 -848-4400 Fax: 510 -848-5614 Lead Investigator: Raffit Hassan, M.D. Thoracic and GI Oncology Branch Head, Solid Tumor Immunotherapy Section Principal Investigator National Cancer Institute 10 Center Drive Building 37, Room 5116 Phone: 301-451-8742 Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page iii STUDY SYNOPSIS Name of Sponsor Company: Aduro Biotech , Inc. Individual Study Table Referring to Part of the Dossier Volume: Page: (For National Authority Use Only) Name of Finished Product: CRS -207; pemetrexed ; cisplatin; cyclophosphamide Name of Active Ingredients: Pemetrexed : C20H19N5Na2O6·7H 2O Cisplatin: PtCl 2H6N2 CRS -207: Lm ΔactA/ΔinlB/hMes o Cyclophosphamide (Cy): C7H15Cl2N2O2P•H 2O Title of Study: A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS -207 in Combination with Pemetrexed and Cisplatin as Front -line Therapy in Adults with Malignant Pleural Mesothelioma Primary Investigator: Raffit Hassan, M.D. Number of Sites: Up to 7 Phase of Development: Phase 1B Treatment Period: 25 Weeks Study Duration: 7 years Objectives: Primary: To determine the safety of CRS -207 (with or without low -dose cyclophosphamide [Cy] given one day prior CRS -207) when administered in combination with pemetrexed and cisplatin and to evaluate the induction of immune response to mesothelin as measured by IFN -gamma ELISPOT assay prior to treatment and at time points during and after treatment. Secondary: To evaluate o bjective tumor response, progression free survival, time to progression, overall survival, and the predictive value of serum mesothelin for therapeutic response for each treatment regimen . Exploratory: i) conduct immune subset analysis (e.g. CD4, CD8, T reg) and gene expression profiling of tumor tissue pre- and post -vaccination; ii) to assess induction of anti -mesothelin humoral immune response; iii) to measure tumor marker kinetics as biomarkers of tumor response ; iv) evaluate the association between pulmo nary function improvement and tumor response; v) evaluate the relationship of tumor response to overall survival . Methodology: This is a phase 1B study to evaluate the safety and induction of immune response of CRS -207 (with or without Cy) in combination with pemetrexed and cisplatin in front -line therapy of adults with malignant pleural m esothelioma (MPM) . Up to 16 subjects were original ly planned to be enrolled in this study.